Login / Signup

Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study).

Alejo Rodriguez-VidaAristotelis BamiasEmilio EstebanMaria Isabel SaezMarta Lopez-BreaDaniel CastellanoCristina CaballeroJose Luis Gonzalez-LarribaEmiliano CalvoSonia MaciaAlain RavaudJoaquim Bellmunt
Published in: BJU international (2020)
The study failed to show any benefit of alternating cycles of sunitinib and everolimus in patients with mRCC. The alternating approach using an mTOR inhibitor does not seem to prevent the occurrence of resistance to VEGFR blockade.
Keyphrases
  • phase ii study
  • open label
  • clinical trial
  • small cell lung cancer
  • risk assessment
  • renal cell carcinoma
  • randomized controlled trial
  • metastatic renal cell carcinoma
  • rectal cancer